Dynorphin
Also known as: Dynorphin A, Dynorphin B, Dynorphin A(1-13), Dynorphin A(1-8), Dynorphin A(1-17), Big dynorphin, Prodynorphin-derived peptide, Pdyn peptide, KOR endogenous ligand
Endogenous opioid neuropeptide — prodynorphin-derived; kappa-opioid receptor (KOR) agonist
What it is
Dynorphin is a naturally occurring brain peptide studied for its roles in pain perception, mood regulation, stress responses, and reproductive hormones. Researchers and clinicians interested in opioid neuroscience, addiction medicine, and chronic pain explore dynorphin's kappa opioid receptor system as a potential target for new treatments for depression, anxiety, and substance use disorders.
The scientific side
dynorphin is a family of endogenous opioid neuropeptides derived from the precursor protein prodynorphin (PDYN), with dynorphin A(1-17) representing the prototypical bioactive form. The peptides act as high-affinity, selective agonists at kappa-opioid receptors (KOR), a class A G protein-coupled receptor (GPCR) that signals through Gi/o proteins to inhibit adenylyl cyclase, reduce cAMP, and suppress neuronal excitability. KOR activation also recruits beta-arrestin pathways that mediate receptor internalization and biased signaling with distinct functional consequences. Dynorphin is co-released with classical neurotransmitters from dense-core vesicles, enabling volume transmission across longer distances than fast synaptic signaling. In the dorsal striatum, endogenous dynorphin release from medium spiny neurons is necessary and sufficient for goal-directed behavior, as demonstrated by conditional deletion and biosensor imaging studies showing time-locked dynorphin dynamics during action-outcome learning. In the hypothalamus, dynorphin is co-expressed with kisspeptin and neurokinin B in KNDy neurons of the arcuate nucleus, which function as the GnRH pulse generator regulating reproductive hormone secretion; dynorphin serves as the key inhibitory signal that terminates LH pulses, and dysregulation of these neurons underlies vasomotor symptoms of menopause (PMIDs: 41981275, 42522579). In pain circuits, spinal dynorphin A expression is upregulated by membrane glucocorticoid receptor signaling in microglia, providing an endogenous analgesic counter-mechanism to inflammatory and neuropathic hypersensitivity. In limbic circuits, the KOR-dynorphin system bidirectionally modulates mood: KOR activation in hippocampus suppresses adult neurogenesis and promotes depression-like behavior via Pax6-dependent mechanisms, while KOR antagonism shows antidepressant and anxiolytic potential across hippocampal-amygdala-prefrontal and VTA-nucleus accumbens circuits (PMIDs: 42399227, 42839386). In addiction, dynorphin signaling in the ventral tegmental area and periaqueductal gray modulates opioid withdrawal severity, with KOR-expressing VTA neurons receiving direct dynorphinergic input that regulates aversive withdrawal behaviors. Dynorphin A also interacts with atypical chemokine receptor 3 (ACKR3), which scavenges opioid peptides via beta-arrestin internalization, limiting dynorphin's availability to classical KOR and suggesting a regulatory buffer in pain and opioid signaling.
Class: Endogenous opioid neuropeptide — prodynorphin-derived; kappa-opioid receptor (KOR) agonist
Administration & storage
- Administration
- Intrathecal (IT) injection — used in rodent spinal pain research; not a clinical route for humansIntracerebroventricular (ICV) injection — used in rodent neuroendocrine research (KNDy circuit studies)Intravenous infusion — used in the NIDA-funded NCT00000244 clinical trial of dynorphin A(1-13) in heroin-dependent participantsSubcutaneous injection — used for peripherally restricted dynorphin A-derived chimeric peptide analogs in rodent models (PMID: 41494468)
- Storage
- Synthetic dynorphin peptides are supplied lyophilized and should be stored at -20°C or -80°C, protected from light and moisture. Reconstituted solutions are unstable due to enzymatic degradation and should be used immediately. Avoid repeated freeze-thaw cycles. Commercial research-grade dynorphin A peptides have a typical shelf life of 12–24 months when stored desiccated at -20°C.
- Cautions
- No approved human therapeutic product: dynorphin is an endogenous neuropeptide with no approved therapeutic indication. Self-administration of synthetic dynorphin peptides outside of clinical trial settings has no established safety profile.,Paradoxical pro-nociceptive effects at high doses: High-dose intrathecal dynorphin A in rodents can paradoxically facilitate pain (dynorphin-induced allodynia and hyperalgesia) via NMDA receptor activation independent of KOR, suggesting a non-linear dose-response in spinal circuits. This effect has not been well characterized in humans (PMIDs: 41276104, 41123265).,KOR-mediated dysphoria and psychotomimetic effects: KOR agonism by dynorphin or synthetic KOR agonists produces dose-dependent dysphoria, sedation, disorientation, and perceptual disturbances in humans, consistent with the aversive role of the KOR-dynorphin system in stress and mood regulation. These represent a significant barrier to clinical KOR agonist development.,Respiratory and cardiovascular effects: Systemic opioid peptides including KOR agonists can cause bradycardia, hypotension, and, at high doses, respiratory depression. The peripheral versus central pharmacokinetics of any dynorphin-based therapeutic would need to be carefully characterized.,Rapid enzymatic degradation: Dynorphin peptides are rapidly cleaved by endogenous proteases (neurolysin, neprilysin, angiotensin-converting enzyme) in plasma and CNS, limiting bioavailability after systemic administration and complicating therapeutic delivery.,Potential for addiction and dependence: KOR systems interact with mesolimbic dopamine and mu-opioid circuits relevant to reward and dependence. Chronic KOR modulation (agonism or antagonism) may have downstream effects on the broader opioid and dopamine systems, including compensatory upregulation of other opioid receptor types.
Legal & regulatory status
Dynorphin itself has no FDA-approved therapeutic product. It is an endogenous neuropeptide studied as a research tool and as a template for drug design. Synthetic dynorphin A (1-13) was investigated in a NIDA-funded…
Dynorphin as an endogenous peptide is not listed on the WADA Prohibited List. However, synthetic kappa-opioid receptor agonists or modulators derived from dynorphin pharmacology could potentially fall under Section S1…
No therapeutic product containing dynorphin or a direct dynorphin analog is approved by Health Canada. The endogenous opioid is recognized in the scientific literature as the primary endogenous ligand for kappa-opioid…
What it's studied for
- Modulation of pain and nociception — endogenous analgesic counter-regulation Preclinical (Animal)
- Depression and anxiety — KOR-dynorphin circuit modulation Preclinical (Animal)
- Goal-directed behavior and striatal learning — neuroscience of action-outcome associations Preclinical (Animal)
- Reproductive neuroendocrinology — GnRH pulse regulation via KNDy neurons Human observational
- Opioid use disorder and withdrawal — KOR-dynorphin aversive signaling Preclinical (Animal)
- Feeding behavior and contextual energy regulation Preclinical (Animal)
- Oncology — tumor-suppressive signaling in triple-negative breast cancer Preclinical (Animal)
- Temporal lobe epilepsy — seizure modulation via neuropeptide co-transmission Mixed
Safety signals
- KOR-mediated dysphoria, sedation, and psychotomimetic effects
- Paradoxical pro-nociceptive effects (dynorphin-induced allodynia) at high spinal doses
- Rapid degradation and unpredictable CNS bioavailability after systemic administration
- Hypothalamic-pituitary-gonadal (HPG) axis disruption — reproductive suppression with sustained KOR activation
- Interactions with opioid dependence circuits — contribution to withdrawal aversion
- Cardiovascular effects — bradycardia and hypotension with KOR agonist administration
- Pro-inflammatory potential at sites of tissue injury — context-dependent dynorphin effects
All studies (7)
Frequently asked
What is dynorphin and what does it do in the brain?
Dynorphin is one of the body's natural opioid peptides — a small protein fragment produced in the brain, spinal cord, and peripheral nervous system. Unlike the endorphins associated with runner's high and pleasure, dynorphin primarily activates kappa-opioid receptors (KOR) and tends to produce inhibitory and sometimes aversive effects, including pain modulation, stress responses, and mood suppression. It plays important roles in regulating pain signals in the spinal cord, setting the pace of reproductive hormones (as part of the KNDy neuron system in the hypothalamus), modulating stress and reward circuits in the brainstem and limbic system, and influencing feeding behavior. Researchers see both its inhibitory functions and its aversive qualities as important targets for developing new treatments for chronic pain, depression, addiction, and menopausal symptoms.
Is dynorphin available as a supplement or injectable peptide?
No. Dynorphin is an endogenous neuropeptide with no approved therapeutic product and is not available as a legal supplement or consumer peptide. While synthetic dynorphin A has been studied in clinical research contexts (including a NIDA-sponsored trial for heroin dependence), it has not been developed into an approved drug. Dynorphin peptides are sold by chemical suppliers for laboratory research use only. Self-administration would carry significant unknown risks, including dysphoria, cardiovascular effects, reproductive hormone disruption, and unpredictable CNS effects, and there is no established safe or effective human dosing protocol outside formal clinical trials.
How is the dynorphin/KOR system related to depression and mood?
The dynorphin-kappa opioid receptor (KOR) system is increasingly recognized as a key driver of stress-induced dysphoria and depressive states. When chronically activated by stress (e.g., through elevated cortisol/corticosterone triggering dynorphin release), KOR signaling in the hippocampus suppresses the growth of new neurons, which is linked to depression-like behavior in animal models. KOR activation in the nucleus accumbens and amygdala also dampens dopamine signaling and amplifies negative emotional states. This is why researchers are developing KOR antagonists — drugs that block dynorphin's receptor — as a potentially novel antidepressant and anxiolytic approach. However, all human evidence so far comes from KOR antagonist drug trials, not from direct dynorphin manipulation.
What is the connection between dynorphin and menopausal hot flashes?
Dynorphin plays a central role in the hypothalamic circuit that triggers hot flashes. In the arcuate nucleus of the hypothalamus, a population of neurons called KNDy neurons (named because they co-produce Kisspeptin, Neurokinin B, and Dynorphin) function as the pacemaker for reproductive hormones. During menopause, falling estrogen levels cause these neurons to become hyperactive. Excess neurokinin B release activates nearby neurons that project to the body's thermoregulatory center, triggering hot flashes. Dynorphin normally acts as an internal brake on KNDy neuron firing, but this brake is less effective when estrogen is low. This discovery has led directly to a new class of FDA-approved non-hormonal hot flash treatments called NK3 receptor antagonists (fezolinetant/Veozah), which dampen the overactive KNDy circuit.
What is dynorphin's role in opioid addiction and withdrawal?
Dynorphin and the KOR system represent a parallel opioid circuit to the mu-opioid receptor system targeted by drugs like heroin and prescription opioids. Chronic use of mu-opioid drugs upregulates dynorphin production in the brain's aversion circuits — particularly in the ventral tegmental area (VTA) and periaqueductal gray (PAG) — and this dynorphin surge drives the aversive, dysphoric experience of opioid withdrawal. In other words, the body's dynorphin system 'fights back' against chronic opioid use, making withdrawal intensely unpleasant and increasing relapse risk. In alcohol use disorder, interactions between dynorphin, corticotropin-releasing factor, and orexin in the prefrontal cortex contribute to stress-triggered alcohol craving and relapse. This has made KOR antagonists candidates for reducing withdrawal severity and preventing relapse.